Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells
about
Advances in the understanding of mechanisms and therapeutic use of bortezomibMitochondrial apoptosis and BH3 mimeticsCellular inhibitor of apoptosis (cIAP)-mediated ubiquitination of phosphofurin acidic cluster sorting protein 2 (PACS-2) negatively regulates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicityHistone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cellsHDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivoVorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expressionOverview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphomaReversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors.High cell surface death receptor expression determines type I versus type II signalingDual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignanciesDeletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma.Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cellsSynergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cellsConstitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells.ABT-737 synergizes with Bortezomib to kill melanoma cells.MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors.BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibitionBiophysical basis of the promiscuous binding of B-cell lymphoma protein 2 apoptotic repressor to BH3 ligands.Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells.Magnetic fluid hyperthermia enhances cytotoxicity of bortezomib in sensitive and resistant cancer cell linesExocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.The fourth dimension in immunological space: how the struggle for nutrients selects high-affinity lymphocytes.Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment.BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size.Metformin Induces Cell Cycle Arrest and Apoptosis in Drug-Resistant Leukemia Cells.Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerizationALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2.BCL-2 family proteins: changing partners in the dance towards death.Proteasome-associated deubiquitinases and cancer.Measurement of BH3-only protein tolerance.Arenobufagin Induces Apoptotic Cell Death in Human Non-Small-Cell Lung Cancer Cells via the Noxa-Related Pathway.Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA
P2860
Q26849940-EE1986EA-21A7-45F2-8595-82FC643DAC58Q28069552-891448D6-5F0F-4FEB-AB51-07D11C022108Q28540934-0DE4D123-39FE-447F-BDCC-3B2683C5943DQ33808800-7F3A0338-583C-49F0-8794-5A40070664C7Q34534191-967B75B4-758F-4E09-B375-8FB48D84637EQ34541123-ED5A9E44-3105-46B1-A157-255019698A6EQ34788381-D8DBD6BE-2E33-4135-88E3-356A0E31D6E8Q35004965-82BDECE7-8900-4FCF-AFC6-E1C555528DC6Q35114769-51FC2668-FF40-44B7-9EF5-7C7C5D9C6339Q35371553-6C480AC5-2A5D-49B8-8C11-EF5C96BC16DFQ35669226-406049CA-DA00-47B5-B086-5C66DB449BD0Q35778422-6C4D3C9E-45FE-4A94-8AEA-9395964DC760Q35840019-65A9D435-7DCA-4279-97DF-F8C449F6A90CQ36057611-8E6919B3-949C-4D1F-99BC-630AA62E59ADQ36121745-933469FA-98AE-4DCF-9306-6FC50089474DQ36199633-2C4EC1B6-F99B-4B85-8EC3-7E48D53BA4FBQ36425600-FEEAA2F7-5B11-40D4-8CD7-84D5653C9DA5Q36751575-E1DF8247-9709-4E8C-B024-EE61FB89A9C4Q37077410-2339240C-5227-40CB-8206-9EFD16C2403DQ37142966-D32D53EA-4A21-4B28-A47C-48DCB1ED7C19Q37260986-1DB8BAA7-8F0A-44B0-9C62-8B8862E16229Q37414942-B966DA09-4D04-4F7E-A2A3-574C4BD1E686Q37688848-9DBAEF49-A827-4353-809B-F4770D3D21E9Q38034268-D9FAF137-67A1-4BF7-9EFB-FA9F9771C593Q38202977-D41CE124-A57D-4B62-8271-2229E2515314Q38398064-A4707105-8077-46C5-8AB8-5586524B6964Q38930539-62D02388-8145-4E1D-91E9-189E7879E9CDQ39300586-46B26D53-2C0F-411E-A700-7771F4F1E25EQ39599213-EB8AFF4F-6E5C-4219-A685-58CBB1CB9250Q42093002-F774BB3A-9C2F-4689-9748-23A31AF8A139Q42800693-85C52170-42F7-4052-96DD-B64DED59C1A0Q42943366-92903F75-B967-4051-9AD0-5C30B4F2B2A6Q47155532-E47F6DA0-9AD7-4BEC-AEED-33BAD06F10A6Q47161331-912E0D4A-6ACC-41D5-9EDF-192248299479Q47624759-70264ABD-67EE-4B54-81F8-579C55BEA1F9Q47690509-4C2950F6-5B5B-4458-8132-B1E9D203D37CQ58765200-CFBA640A-D343-41FE-A0D0-2E943262E278
P2860
Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Noxa/Bcl-2 protein interaction ...... stance in human lymphoid cells
@ast
Noxa/Bcl-2 protein interaction ...... stance in human lymphoid cells
@en
Noxa/Bcl-2 protein interaction ...... stance in human lymphoid cells
@en-gb
Noxa/Bcl-2 protein interaction ...... stance in human lymphoid cells
@nl
type
label
Noxa/Bcl-2 protein interaction ...... stance in human lymphoid cells
@ast
Noxa/Bcl-2 protein interaction ...... stance in human lymphoid cells
@en
Noxa/Bcl-2 protein interaction ...... stance in human lymphoid cells
@en-gb
Noxa/Bcl-2 protein interaction ...... stance in human lymphoid cells
@nl
prefLabel
Noxa/Bcl-2 protein interaction ...... stance in human lymphoid cells
@ast
Noxa/Bcl-2 protein interaction ...... stance in human lymphoid cells
@en
Noxa/Bcl-2 protein interaction ...... stance in human lymphoid cells
@en-gb
Noxa/Bcl-2 protein interaction ...... stance in human lymphoid cells
@nl
P2093
P2860
P921
P356
P1476
Noxa/Bcl-2 protein interaction ...... stance in human lymphoid cells
@en
P2093
Alyson J Smith
Cristina Correia
Haiming Dai
Ingo Schmitz
Rie Takahashi
Scott H Kaufmann
Sun-Hee Lee
P2860
P304
P356
10.1074/JBC.M110.189092
P407
P577
2011-05-20T00:00:00Z